Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
Major Study Reveals Barriers to Implementing AI Chest Diagnostics in NHS Hospitals
A UCL-led study identifies significant challenges in deploying AI tools for chest diagnostics across NHS hospitals in England.
•EurekAlert
AI Model Enhances Prediction of Infection Risks from Oral Mucositis in Stem Cell Transplant Patients
Researchers developed an explainable AI tool that accurately predicts infection risks related to oral mucositis in hematopoietic stem cell transplant patients.
•EurekAlert
AI-Enabled Hydrogel Patch Provides Long-Term High-Fidelity EEG and Attention Monitoring
Researchers unveil a reusable hydrogel patch with machine learning capabilities for high-fidelity EEG recording and attention assessment.